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Editorial 
THE EPIDEMIOLOGY OF CANCER OF THE PROSTATE 
(Received 28 November 1974) 
1N 1969, 16,836 men in the United States were reported as having died of cancer of the 
prostate. The mortality rate of 17.1 per 100,000 for this site was second only to that for 
cancer of the lung [l]. The American Cancer Society has estimated that 38,000 new 
cases of the disease are diagnosed each year [2]. Yet the cause of this common cancer 
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sive reviews of the epidemiology of cancer of the prostate have been published [3, 41. 
Certain facts are clear. Cancer of the prostate increases steadily with age from about 
40 and is rare under 50 yr of age. There are large international differences both in 
incidence [5] and in mortality [6, 71. Rates are high in the United States, particularly 
among negroes, but they are low in oriental peoples particularly amongtheJapanesein 
Japan. These low rates are largely confined to clinical cancer since autopsy data have 
shown that latent cancer is almost as frequent in Japanese as in Caucasian males of 
similar age [&lo]. Migration appears to influence the liability to the clinical disease. 
Japanese and Polish immigrants to the United States have higher death rates than 
Japanese and Poles in their native lands [l 1, 121. The increased rates suggest that 
environmentai factors not previousiy operative before emigration may be important. 
Migration may also possibly explain the association of cancer of the prostate with 
religion. The disease has long been known to be relatively uncommon in Jews [13]. A 
study of mortality in the three main religious groups in New York City for the years 
1953-1958 [14] showed that the rates for Jews were 83 per cent of those for Catholics 
and only 64 per cent of those for Protestants. The recent study by Wynder and his 
colleagues [4] suggests that this association now holds only for men aged 70 and over. 
A high proportion of Jews in this age group in N.Y.C. came from Russia and Poland, 
countries where death rates from cancer of the prostate are low. Furthermore in 
Israel where mortality rates for this cancer are relatively low, the incidence is higher in 
Jews originating in Africa or Europe than in Jews from Asia or Jews born in Israel [ 151. 
Cancer of the prostate appears to be fairly consistently related to marital status [3]. 
Mortality rates for cancer of the male genital organs (90 per cent of them prostate) are 
higher in the ever married than in single persons with the highest rates in the widowed 
and divorced. Furthermore there is a suggestion that the increased rates among the 
married may be mainly in those who have had children [16]. Mortality rates from 
prostatic cancer among priests are clearly of interest in this connection. No study 
appears to have been made. During the years 1949-1953 in England and Wales the 
Registrar General reported that two Roman Catholic priests aged 65 yr and over died 
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of cancer of the prostate whereas five would have been expected [17]. The relationship 
with marital status suggests that sexual factors may be important. To date there have 
been very few investigations of sexual practices in relation to cancer of the prostate. A 
comparison of a small number of cases with age matched controls [18], suggested that 
patients with prostatic cancer had a greater sexual drive as indicated by multiple 
sexual partners, extra-marital activity and frequency of venereal infection. Although 
doubt has been cast on the significance of sexual factors by recent studies [4, 191 the 
populations investigated were not ideal for demonstrating them. Further observations 
on sexual behavior in relation to cancer of the prostate are urgently needed. 
Heredity may be important. A higher frequency of prostatic cancer in the relatives 
of patients with the disease than in the relatives of controls has been a consistent 
finding in those few studies which have looked into the question [20]. A higher 
frequency of blood group A in prostatic cancer cases has been reported [21] but has 
not been confirmed [4]. Prostatic cancer has often been found to be commoner in 
urban than in rural areas [3]. The reason for this is uncertain; but the observation in 
Buffalo that mortality was positively correlated with levels of total suspended particu- 
lates [22] suggests that air pollution may contribute. Mortality statistics by area from 
England and Wales [23] do not however provide much support for air pollution as a 
major factor in the disease. Socioeconomic circumstances are not consistently related 
to cancer of the prostate [24,25] nor do occupational mortality statistics point to any 
occupational exposures. The higher rates sometimes noted in the professional classes 
probably reflect more accurate diagnosis. The suggestion that workers exposed to 
cadmium fumes [26, 271 may have an excess risk of developing this cancer however 
deserves to be followed up. Cancer of the prostate does not appear to be consistently 
related to prostatitis (though more information on infection is needed), calculus, 
circumcision, tobacco smoking or alcohol ingestion [4]. 
Cancer of the prostate is often thought of as a hormone-dependent cancer partly 
because of the experimental demonstration of regression following castration or 
estrogen therapy [28] and partly because of the finding at autopsy of multiple endo- 
crine changes [29]. The correlation of cancer of the prostate with cancer of the breast 
has also been advanced in support for this view [30]. Although much of the bio- 
chemical evidence is contradictory, recent studies of urinary hormone metabolites in 
patients and healthy controls [31, 321 have shown that cancer cases excrete less 
androsterone, have a lower estrogen/etiocholanolone ratio and excrete a higher 
proportion of total estrogen as estrone and estradiol than control subjects. There does 
not however appear to be consistent differences in hormone levels between Americans 
and Japanese. Nor have studies which have included hair distribution as a measure of 
hormone levels revealed any consistent differences between cancer cases and controls 
[33]. A report that cancer of the prostate is less common at autopsy in patients with 
cirrhosis of the liver [34], a condition in which estrogen levels are high [35], may be 
of some significance in this connection. 
The relationship of benign prostatic hyperplasia (BPH) to cancer of the prostate, is 
controversial. The two conditions are common, especially if latent prostatic cancer is 
included; both increase progressively with age. By chance therefore they will often be 
found to coexist. There have however been some indications that BPH may be a 
precursor of prostatic cancer [29]. Two epidemiological papers have recently des- 
cribed well-controlled investigations of the relationship between BPH and prostatic 
The Epidemiology of Cancer of the Prostate 345 
cancer. Armenian and his colleagues [36] conducted both prospective and retrospective 
studies. In the prospective study, 345 patients with BPH but with no evidence of 
prostatic or other malignancies, who were admitted to Roswell Park Memorial 
Institute between 1945 and 1965 were identified. Seven incorrectly diagnosed cases 
were excluded and the remaining 338 cases were matched for age and time of admission 
with randomly selected patients discharged during the same period with a diagnosis of 
nonneoplastic disease. Cases and controls were followed until 31 December, 1972 
through the case notes when these were complete and by searching for death certificates 
and cancer registry reports at the New York State Health Department for the re- 
mainder. Follow-up was equally complete for both groups, 87.6 per cent of the cases 
and 88.5 per cent of the controls being traced. The total number of person-years of 
follow-up was similar, 2540 for the cases and 2285 for the controls. The death rate from 
prostatic cancer among patients with BPH was 10.1 per 1000 person-years compared 
with 2.7 per 1000 person-years among the controls, giving a relative risk of 3.7 times 
greater among the BPH patients. Death rates in the study group were higher than the 
age adjusted rates for New York State in 1960. But the proportional mortality from 
prostatic cancer among the controls was similar to that for the State. Among those who 
underwent prostatectomy, prostatic cancer rates were 5.1 per 1000 person-years 
whereas among those who did not the rates were 11.3 per 1000 person-years, suggesting 
a considerable reduction in subsequent cancer risk from the operation. 
In the retrospective study 290 patients with prostatic cancer were matched with 290 
controls with a non-neoplastic final diagnosis. Matching was for age and period of 
admission (1957-1965). Information on previous admissions were copied from the 
records and coded, without knowledge of the diagnosis, for reason of admission and 
index of suspicion of cancer. One hundred and four of the cancer cases had previously 
been admitted for prostatic disease compared with only 27 of the controls. Sixteen 
of the BPH cases and one control were coded blindly as suspected prostatic cancer. 
One prostate-cancer patient had been previously admitted for prostatitis. A matched 
pair analysis on the remaining 87 possible BPH admissions among the cancer cases and 
21 such admissions among the controls indicated a relative risk of 5.1 for prostatic 
cancer. This difference was not eliminated by considering different intervals between 
index and antecedent hospital admissions. Thus in both prospective and retrospective 
studies an increased risk of prostatic cancer from BPH was clearly shown. 
These findings are at variance with a study carried out by Greenwald and his 
colleagues [37]. This was based on 838 men who had had subtotal prostatectomy at the 
Lahey Clinic Foundation, Boston, Mass. during the period 1940-1959. All were under 
80 yr of age and histological examination had indicated prostatic hyperplasia with no 
evidence of malignancy. These patients were matched with men in the same 5-yr age 
group who had had surgery at the same time for some other condition but who had no 
known disease of the prostate or malignancy at the time of surgery. Follow-up was 
similar for both groups; 88 per cent of the cases and 91 per cent of the controls were 
followed to death or the termination of the study (31 December, 1970). Tracing was 
through review of clinic records, letters to patients, family members and physicians, 
supplemented when appropriate by examination of voting lists, city directories and 
similar sources. Diagnosis of prostatic cancer was based on hospital records, pathology 
reports, letters from physicians, copies of abstracts of death certificates and autopsy 
reports. Duration of follow-up was comparable for the two groups, 10.7 yr for the 
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cases and 11.2 yr for the controls, the small difference reflecting a slightly higher 
mortality among the BPH cases. Twenty-four (2.9 per cent) of the 835 BPH cases and 
26 (3.2 per cent) of the 802 controls developed cancer of the prostate. No differences 
were found on analysis by specific 5-yr age groups. When the data were analyzed using a 
modified life table method 3.0 cases of prostatic cancer developed per 1000 person-years 
among the BPH group compared with 3.1 cases per 1000 person-years among the con- 
trols. The relative risk of prostatic cancer in the BPH group was estimated to be 0.88. 
How can the discrepancy between these two groups of workers be explained? One 
obvious explanation is that the Lahey Clinic BPH group had been treated by pros- 
tatectomy which might be expected to reduce the risk of cancer and indeed was 
shown to do so by Armenian and his colleagues. But even in their prostatectomy 
group these workers noted an approximately twofold increased risk of cancer. It is 
possible that in their prospective study, patients with undetected cancer at entry may 
have been included among the BPH cases since R.P.M.I. is a cancer referral center. No 
information is given about the number of hyperplasia cases who were referred because 
of a suspicion of cancer. The possibility that the BPH patients had a greater chance 
of having prostatic cancer detected was however considered bytheseworkers. Although 
this possibility could not be entirely eliminated, the authors considered it to be 
unlikely because of the reduction in risk shown to be associated with prostatectomy. 
Bias could have been introduced into the study by Greenwald and his colleagues 
through the exclusion of cancer by histological examination of the excised prostates. 
By eliminating latent disease from their case group but not from their controls it 
seems possible that a twofold increase in risk of clinical cancer might have also been 
eliminated. It would be interesting to know what percentage of BPH prostatectomies 
were excluded because of latent cancer. Not only might this explain the discrepancy in 
the findings in these two studies, it might also afford a good opportunity for estimating 
the rate of progression of latent to clinical cancer, a point on which there is dis- 
agreement [38]. 
Armenian and his colleagues suggest a randomized controlled trial of the effect of 
prostatectomy in symptom-free patients with BPH who had additional epidemiologic 
characteristics associated with a high risk of prostate cancer. They estimate that if the 
prevalence of BPH in men over 50 is 30 per cent and the risk of cancer is 3.5 times 
greater in those with BPH, 43 per cent of all prostatic cancer may be attributed to BPH. 
Prophylactic prostatectomy in such cases should very materially reduce the incidence 
of this highly fatal form of cancer. Although potentially an extremely interesting study, 
one might anticipate a certain reluctance on the part of symptom-free patients to 
participate. The suggestion by Wynder and his colleagues that elucidation of the 
etiology of cancer of the prostate needs close team work of epidemiologists, pathol- 
ogists, nutritional biochemists and steroid chemists concentrating particularly on the 
differences in clinical (and I might add latent) cancer in Caucasians, Negroes, native 
Japanese and immigrants to the U.S. should be heeded. 
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